Saturday, July 21, 2018 11:56:10 AM
Having held Hercules in my own portfolio now for exactly one month, I'm seeing a gain of 4 pennies shy of a whole dollar. it should be obvious to one (me) and all (you) that this could prove to be one of the most outstanding plays of the year for a high yield hound.
This pick may well be the first item on my short list when that juicy NGL distribution comes in to the tune of $17,50?. Toss in a few other distributions from different picks and that leaves me with $18,000 to play with.
Perhaps $5K will go into my checking account to sit alongside the long established cash reserves (dry powder). Another $5K or so will bring a bit of relief to the margin utilization. The rest, half of which will be sitting in three sheltered accounts---will be spread out among several plays. NGL will be the recipient of of a very small amount through a DRIP in a tiny IRA. Another IRA will be similarly handled. Most of the NGL bounty will be in the form of cash.
Hercules will definitely be in line for a transfusion as it's been so profitable already. I've not yet decided how to disperse the funds but this will be foremost in my mind as the next few weeks roll on by.
More on this to come.
However, I've gotta wonder why I find myself alone here? This is so profitable already! And take a look at the Barchart opinion option and you'll find 100% buy signals all over the place. Ditto with CEQP, by the way.
If you're not sure about launching a position in a BDC, read up on it. As you do, consider the impact on smaller businesses in America and how you expect they'll fare as the current administration continues to fight for the little business entities. I think you'll sense a new imperative and frankly there's no time like the present to make a move.
Let me know what you do, please.
Recent HTGC News
- Hercules Capital Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 08:05:00 PM
- Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024 • Business Wire • 04/30/2024 10:00:00 AM
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab • PR Newswire (US) • 04/30/2024 07:00:00 AM
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab • PR Newswire (US) • 04/30/2024 07:00:00 AM
- Hercules Capital Celebrates 20th Anniversary with $20.0 Billion in Cumulative Originations • Business Wire • 04/24/2024 10:00:00 AM
- Hercules Capital Announces Date for Release of First Quarter 2024 Financial Results and Conference Call • Business Wire • 04/18/2024 10:00:00 AM
- Hercules Capital Receives BBB- Affirmed Investment Grade Credit and Corporate Rating from Fitch Ratings, Inc. • Business Wire • 03/27/2024 10:00:00 AM
- Hercules Capital Receives Confirmed BBB Investment Grade Rating with Revised Outlook to Positive from Morningstar DBRS • Business Wire • 03/21/2024 10:00:00 AM
- Hercules Capital Announces Upcoming Event for the Financial Community • Business Wire • 02/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:31:11 PM
- Hercules Capital Reports Fourth Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:07:00 PM
- Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the Fourth Quarter 2023 • Business Wire • 02/13/2024 11:02:00 AM
- Hercules Capital Announces New Supplemental Cash Distribution of $0.32 per Share • Business Wire • 02/13/2024 11:00:00 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 01/30/2024 10:40:32 PM
- Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2023 Financial Results and Conference Call • Business Wire • 01/25/2024 11:00:00 AM
- Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital • GlobeNewswire Inc. • 01/23/2024 09:05:00 PM
- Form ABS-15G - Asset-backed securitizer report pursuant to Section 15G • Edgar (US Regulatory) • 01/22/2024 04:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 12:47:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 12:47:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 12:46:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 01:29:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 01:28:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 01:28:28 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM